QTc prolongation among hydroxychloroquine sulfate-treated COVID-19 patients: An observational study

Fteiha, Bashar; Karameh, Hani; Kurd, Ramzi; Ziff-Werman, Batsheva; Feldman, Itamar; Bnaya, Alon; Einav, Sharon; Orlev, Amir; Ben‐Chetrit, Eli

doi:10.22541/au.159238989.99123083

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study in SARS‐CoV‐2 patients reported an increase of 13 (IQR 9–16) ms 41 . Other studies reported QTcF‐prolongation after hydroxychloroquine treatment only in a minority of their cases 43,44 . For example, an average increase of the QTcF‐interval of 1.8% was observed in a cohort of 219 hospitalized and ambulatory SARS‐CoV‐2 patients who were treated with a total dose of 2800 mg hydroxychloroquine, although combined with other antiviral drugs 40 .…”

Section: Discussionmentioning

confidence: 99%

“…40 Another study in SARS-CoV-2 patients reported an increase of 13 (IQR 9-16) ms. 41 Other studies reported QTcFprolongation after hydroxychloroquine treatment only in a minority of their cases. 43,44 For example, an average increase of the QTcF-interval of 1.8% was observed in a cohort of 219 hospitalized and ambulatory SARS-CoV-2 patients who were treated with a total dose of 2800 mg hydroxychloroquine, although combined with other antiviral drugs. 40 In another cohort of 111 hospitalized SARS-CoV-2 patients who were treated with a hydroxychloroquine dose similar to our study (2400 mg), only 5 (7%) of the patients developed a QTcF-prolongation.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of hydroxychloroquine on the cardiac ventricular repolarization: A randomized clinical trial

Maarse

Graff

Kanters

et al. 2021

Brit J Clinical Pharma

View full text Add to dashboard Cite

What is already known about this subject? Hydroxychloroquine has been used as anti-malarial and anti-rheumatic drug for decades, with only very few reports of cardiac death after use of this drug.The current SARS-Cov-2 pandemic has raised renewed attention on hydroxychloroquine. Concerns were raised on the pro-arrhythmic effects of hydroxychloroquine, that are presumably caused by blockage of the cardiac hERG channel. This study analyzed the effect of hydroxychloroquine, dosed in a regular regimen for SARS-CoV-2 patients, on the ventricular repolarization in a concentration-effect analysis. What does this study add? There were no significant associations between hydroxychloroquine concentration and ECG characteristics, including QTcF-interval and T-wave morphology, measured with a Morphology Combination Score (MCS). Based on this analysis, hydroxychloroquine does not significantly affect the QTcFinterval and does not significantly increase the risk of arrhythmias in the studied dosing regimen and population. This outcome can be explained by the maximal plasma concentration of this dosing regimen, that is not high enough to exert hERG channel inhibition.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Effect of hydroxychloroquine on the cardiac ventricular repolarization: A randomized clinical trial

Maarse

Graff

Kanters

et al. 2021

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…In observed observational studies, the outcomes below have been reported. In these studies, it was reported that a percentage of participants received from HCQ had prolonged QTc intervals (Ip et al, 2021;Sogut et al, 2021;Fteiha et al, 2020). In the study by Sogut et al (2021), 91.4% of the participants showed significant improvement, however 13 had adverse events (Sogut et al, 2021).…”

Section: Average Of 65 Yearsmentioning

confidence: 98%

Efeitos farmacológicos da hidroxicloroquina em pacientes com COVID-19: Revisão sistemática da literatura

Araújo¹,

Rocha²,

Marques³

et al. 2021

RSD

View full text Add to dashboard Cite

Um surto do novo coronavírus (COVID-19) teve início em dezembro de 2019 e se espalhou pela China, alastrando-se pelo mundo em pouco tempo, o que requer pesquisas imediatas para seu tratamento. Assim, o uso de cloroquina (CQ) e hidroxicloroquina (HCQ) tem despertado interesse no COVID-19. Esta revisão sistemática segue os itens de relatório indicados para revisões sistemáticas e Diretrizes de Meta-Análise (PRISMA). Os descritores selecionados foram: “SARS-CoV-2”, “COVID-19”, “Hydroxychloroquine” e “Chloroquine” e incluídos nas bases de dados Science Direct, United States National Library of Medicine (PubMed), informações bibliográficas latino-americanas em saúde ciências (LILACS), Scientific Electronic Library Online (SciELO) e Web of Science para busca de estudos. Após a triagem, um total de 6.339 estudos foram encontrados. Após a leitura e aplicação dos critérios de elegibilidade, foram selecionados 8 artigos para elaboração dos resultados desta revisão. Os resultados dos estudos mostraram que o uso de HCQ apresenta desfechos sem melhora significativa do quadro clínico, incluindo associação com eventos adversos (inclusive graves) em pacientes com COVID-19. Assim, os ensaios clínicos randomizados não forneceram evidências de eficácia da HCQ em pacientes com COVID-19, mostrando que a HCQ não é significativamente eficaz e apresenta resultados negativos em relação à sua segurança para pacientes com COVID-19.

show abstract

Global prevalence and effect of comorbidities and smoking status on severity and mortality of COVID-19 in association with age and gender: a systematic review, meta-analysis and meta-regression

Chenchula

Vidyasagar²,

Pathan

et al. 2023

Sci Rep

View full text Add to dashboard Cite

A COVID-19 patient often presents with multiple comorbidities and is associated with adverse outcomes. A comprehensive assessment of the prevalence of comorbidities in patients with COVID-19 is essential. This study aimed to assess the prevalence of comorbidities, severity and mortality with regard to geographic region, age, gender and smoking status in patients with COVID-19. A systematic review and multistage meta-analyses were reported using PRISMA guidelines. PubMed/MEDLINE, SCOPUS, Google Scholar and EMBASE were searched from January 2020 to October 2022. Cross-sectional studies, cohort studies, case series studies, and case–control studies on comorbidities reporting among the COVID-19 populations that were published in English were included. The pooled prevalence of various medical conditions in COVID-19 patients was calculated based on regional population size weights. Stratified analyses were performed to understand the variations in the medical conditions based on age, gender, and geographic region. A total of 190 studies comprising 105 million COVID-19 patients were included. Statistical analyses were performed using STATA software, version 16 MP (StataCorp, College Station, TX). Meta-analysis of proportion was performed to obtain pooled values of the prevalence of medical comorbidities: hypertension (39%, 95% CI 36–42, n = 170 studies), obesity (27%, 95% CI 25–30%, n = 169 studies), diabetes (27%, 95% CI 25–30%, n = 175), and asthma (8%, 95% CI 7–9%, n = 112). Moreover, the prevalence of hospitalization was 35% (95% CI 29–41%, n = 61), intensive care admissions 17% (95% CI 14–21, n = 106), and mortality 18% (95% CI 16–21%, n = 145). The prevalence of hypertension was highest in Europe at 44% (95% CI 39–47%, n = 68), obesity and diabetes at 30% (95% CI, 26–34, n = 79) and 27% (95%CI, 24–30, n = 80) in North America, and asthma in Europe at 9% (95% CI 8–11, n = 41). Obesity was high among the ≥ 50 years (30%, n = 112) age group, diabetes among Men (26%, n = 124) and observational studies reported higher mortality than case–control studies (19% vs. 14%). Random effects meta-regression found a significant association between age and diabetes (p < 0.001), hypertension (p < 0.001), asthma (p < 0.05), ICU admission (p < 0.05) and mortality (p < 0.001). Overall, a higher global prevalence of hypertension (39%) and a lower prevalence of asthma (8%), and 18% of mortality were found in patients with COVID-19. Hence, geographical regions with respective chronic medical comorbidities should accelerate regular booster dose vaccination, preferably to those patients with chronic comorbidities, to prevent and lower the severity and mortality of COVID-19 disease with novel SARS-CoV-2 variants of concern (VOC).

show abstract

QTc prolongation among hydroxychloroquine sulfate-treated COVID-19 patients: An observational study

Cited by 3 publications

References 0 publications

Effect of hydroxychloroquine on the cardiac ventricular repolarization: A randomized clinical trial

Effect of hydroxychloroquine on the cardiac ventricular repolarization: A randomized clinical trial

Efeitos farmacológicos da hidroxicloroquina em pacientes com COVID-19: Revisão sistemática da literatura

Global prevalence and effect of comorbidities and smoking status on severity and mortality of COVID-19 in association with age and gender: a systematic review, meta-analysis and meta-regression

Contact Info

Product

Resources

About